This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

DosingClinical Study DataSafety ProfileSupport and ResourcesVideosMaterialsPatient SupportTherapy Management Strategies in Clinical PracticeBy Your Side™ App

The content of this website has been produced in line with the INLYTA® (axitinib) Summary of Product Characteristics for Great Britain. 
Prescribing Information for INLYTA® (axitinib) click here. Prescribing Information for SUTENT® (sunitinib malate) click here. Adverse event reporting information can be found at the bottom of the page.

EfficacyMode of Action

INLYTA® is an inhibitor of multiple receptor tyrosine kinases (TKIs), including vascular endothelial growth factor receptors (VEGFR) required for angiogenesis.1 Dysregulation of the VEGF pathway is frequently associated with RCC, due to loss of function of the von Hippel-Lindau gene2, making mRCC a highly vascular tumour, and underlying why the VEGF pathway continues to be a target in RCC.2

Short Half-Life

'Half-life' is an estimate of the time that it takes for the amount of medicine in the body (usually measured as blood concentration) to be reduced by half

The short half-life of INLYTA® ensures that it is cleared more quickly following dose interruptions/discontinuations3,4

​​​​​​The half-life of INLYTA® is shorter than many of the other therapies used in mRCC (see Table below for a selection)3,5-12
Scroll left to view table
INLYTA® 2.5-6.1 hours
Sorafenib ~ 25-48 hours
Lenvantinib ~ 28 hours
Everolimus ~ 30 hours
Cabozantinib ~ 110 hours
Tivozanib 108-122.4 hours
Sunitinib 40-60 hours (Sunitinib) and 80-110 hours (active metabolite of Sunitinib) 
Pazopanib 30.9 hours
Nivolumab 25 days

A short half-life means that AEs have the potential to be resolved quickly after treatment interruption4

Clinical Study DataAXIS2
Study Design 

A randomised, multicentre, Phase III trial in 723 patients with mRCC with disease progression on first-line therapy (sunitinib or cytokine), comparing the efficacy and safety of INLYTA® 5mg twice daily and sorafenib 400 mg twice daily. 

INLYTA® is the only VEGFR-TKI that delivered superior outcomes vs another TKI after first-line sunitinib or cytokine in Phase III, second-line settings2,3

In a phase III clinical trial, INLYTA® demonstrated superior efficacy over sorafenib as second-line therapy2,3

PFS (primary endpoint)
Median PFS (ITT population) with INLYTA® vs sorafenib3

​Kaplan-Meler curve of progression-free survival assessed by blinded independent radiology review committee for the overal ITT population (adapted from INLYTA® Summary of Product Characteristics)2,3

ORR (secondary endpoint)ORR with INLYTA® vs sorafenib3

ORR in the overall ITT population assessed by blinded independent radiology review committee (adapted from INLYTA® Summary of Product Characteristics)2,3

SafetyCommon treatment-emergent all-causality (non-laboratory) adverse events2
Safety

RCC : Renal Cell Carcinoma, ​​​​​​​aRCC : advanced Renal Cell Carcinoma

References

Chow LQ and Eckhardt SG. J clin Oncol 2007;25:884-896.Rini BI, et al. Lancet 2011;378(9807):1931-1939INLYTA® Summary of Product Characteristics for Great Britain click here. INLYTA® Summary of Product Characteristics for Northern Ireland click here.Schmidinger M, et al. Future Oncol 2018;14:861–875.Sorafenib Summary of Product Characteristics. Bayer. Available at: https://www.medicines.org.uk/emc/product/226/smpc. Accessed: February 2022.Lenvatinib Summary of Product Characteristics. Eisai. Available at: https://www.medicines.org.uk/emc/product/7881/smpc. Accessed: February 2022.Everolimus Summary of Product Characteristics. Novartis. Available at: https://www.medicines.org.uk/emc/product/6658/smpc. Accessed: February 2022.Cabozantinib Summary of Product Characteristics. Ipsen. Available at: https://www.medicines.org.uk/emc/product/4331/smpc. Accessed: February 2022.Nivolumab Summary of Product Characteristics. BMS. Available at: https://www.medicines.org.uk/emc/product/6888. Accessed: February 2022.Pazopanib Summary of Product Characteristics. Novartis. Available at: https://www.medicines.org.uk/emc/product/7861/smpc. Accessed: February 2022.Sunitinib Summary of Product Characteristics. Pfizer. ​​​​​Available at: https://www.medicines.org.uk/emc/product/227/smpc. Accessed: February 2022.Tivozanib Summary of Product Characteristics. EUSA. Available at: https://www.medicines.org.uk/emc/product/8995/smpc. Accessed: February 2022.
PP-INL-GBR-0814. February 2022
Safety Indication

INLYTA® is indicated for the treatment of adult patients with advanced renal cell carcinoma (aRCC) after failure of prior treatment with sunitinib or a cytokine1

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2023 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7284. November 2023
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​